carbamates has been researched along with Central Nervous System Disease in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mean pharmacokinetic parameter values: T1/2 = 5." | 2.68 | A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. ( Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH, 1997) |
| "Atropine sulfate was found to have a clear beneficial CNS effect in addition to its known peripheral antimuscarinic effect." | 1.28 | Carbamate and organophosphate poisoning in early childhood. ( Shahak, E; Sofer, S; Tal, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wiciński, M | 1 |
| Puk, O | 1 |
| Malinowski, B | 1 |
| Schwarz, M | 1 |
| Glick, D | 1 |
| Loewenstein, Y | 1 |
| Soreq, H | 1 |
| Sklarin, NT | 1 |
| Lathia, CD | 1 |
| Benson, L | 1 |
| Grove, WR | 1 |
| Thomas, S | 1 |
| Roca, J | 1 |
| Einzig, AI | 1 |
| Wiernik, PH | 1 |
| Pazdur, R | 1 |
| Meyers, C | 1 |
| Diaz-Canton, E | 1 |
| Abbruzzese, JL | 1 |
| Patt, Y | 1 |
| Grove, W | 1 |
| Ajani, J | 1 |
| Rowinsky, EK | 1 |
| Long, GS | 1 |
| Noe, DA | 1 |
| Grochow, LB | 1 |
| Bowling, MK | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Lifshitz, M | 1 |
| Shahak, E | 2 |
| Sofer, S | 2 |
| Tal, A | 1 |
| Agapejev, S | 1 |
| Vassiliev, I | 1 |
| Lima, MM | 1 |
| Carroll, MN | 1 |
| Golinko, RJ | 1 |
| Lyon, AF | 1 |
| Dunst, M | 1 |
| René, HF | 1 |
| Ford, DH | 1 |
2 reviews available for carbamates and Central Nervous System Disease
| Article | Year |
|---|---|
Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug.
Topics: Animals; Carbamates; Central Nervous System Diseases; Chlorophenols; Drug Repositioning; GABA-A Rece | 2021 |
Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons.
Topics: Carbamates; Central Nervous System Diseases; Cholinesterase Inhibitors; Cholinesterases; Gene Expres | 1995 |
3 trials available for carbamates and Central Nervous System Disease
| Article | Year |
|---|---|
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central N | 1997 |
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Col | 1997 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relat | 1997 |
4 other studies available for carbamates and Central Nervous System Disease
| Article | Year |
|---|---|
Carbamate and organophosphate poisoning in young children.
Topics: Adult; Carbamates; Central Nervous System Diseases; Child; Child, Preschool; Cholinesterases; Humans | 1999 |
Carbamate and organophosphate poisoning in early childhood.
Topics: Atropine; Carbamates; Central Nervous System Diseases; Child; Child, Preschool; Coma; Diagnosis, Dif | 1989 |
[Neurologic manifestations in 93 patients with exogenous poisoning caused by non-therapeutic chemical substances].
Topics: Adolescent; Adult; Arsenic Poisoning; Carbamates; Central Nervous System Diseases; Child; Female; He | 1986 |
CNS-evoked coronary changes and cardiac arrhythmias--anti-arrhythmic properties of mebutamate.
Topics: Animals; Arrhythmias, Cardiac; Carbamates; Central Nervous System Diseases; Dogs; Electric Stimulati | 1968 |